BioMarin posts first $1 billion quarter, sets VOXZOGO PDUFA date for hypochondroplasiaNov 2Quarterly updateBiomarin Pharmaceutical Incvosoritide
Inozyme Pharma halts infant ENPP1/ABCC6 trial of INZ-701 after enrolling 9Oct 15Trial updateBiomarin Pharmaceutical Inc
BioMarin details Alesta deal charges, confirms no change to prior 2026 guidance basisOct 6Quarterly updateBiomarin Pharmaceutical Inc
BioMarin and Ascendis sign settlement and license agreement over CNP patentsSep 30PartnershipBiomarin Pharmaceutical Inc
BioMarin halts VOXZOGO development for Noonan syndrome in childrenSep 15RestructuringBiomarin Pharmaceutical Incvosoritide
BioMarin and Ascendis settle global patent dispute over YuviwelAug 31PartnershipAscendis Pharma A/SBiomarin Pharmaceutical Inc
BioMarin to acquire Alesta Therapeutics for its oral HPP drug candidate ALE1Aug 18M&ABiomarin Pharmaceutical Inc
BioMarin raises 2026 revenue and VOXZOGO guidance, discontinues BMN 401Aug 6Quarterly updateBiomarin Pharmaceutical Incvosoritide
Amicus reports FY2025 results as BioMarin merger deal proceedsJul 13PeopleBiomarin Pharmaceutical Inc